Journal of Emergency Health Care
Formerly known as: International Journal of Medical Investigation
Volume 4, Issue 3 (September 2015)
J Emerg Health Care 2015, 4(3): 289-292 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Farokhi F, Razaviyan J, kosaryan M, Roudbari M, Esmaeili Reykande S, Aliasghariyan A et al . The relationship between serum vascular endothelial growth factor (SVEGF) and beta thalassemia major. J Emerg Health Care 2015; 4 (3) :289-292
URL: http://intjmi.com/article-1-178-en.html
URL: http://intjmi.com/article-1-178-en.html
The relationship between serum vascular endothelial growth factor (SVEGF) and beta thalassemia major
Farzane Farokhi * 
, Javad Razaviyan , Mehrnoush Kosaryan , Mostafa Roudbari , Samira Esmaeili Reykande , Aily Aliasghariyan , Maryam Dehghani
, Javad Razaviyan , Mehrnoush Kosaryan , Mostafa Roudbari , Samira Esmaeili Reykande , Aily Aliasghariyan , Maryam Dehghani
Dep. of Biology, Azad University of Sari Branch, Mazandaran, Iran
Abstract: (9747 Views)
Abstract Background: Beta thalassemia is an inherited disorder characterized by absent or reduced amounts of beta globin chains. Vascular Endothelial Growth Factor (VEGF) is a significant regulator of hemangioblast differentiation. This study was aimed to assess serum VEGF levels in patients with beta thalassemia major in comparison with control group. Methods: This historical cohort study was conducted on 36 patients with β–thalassemia major who had received regular blood transfusion and 26 healthy people which were referred for checkup in a general hospital, Sari, north of Iran, during March to May 2015. Demographic characterization and laboratory tests such as Complete Blood Count (CBC), and evaluation of levels of serum ferritin, serum VEGF, hepatitis B virus antibody and hepatitis C virus antibody were carried out for our patients. The statistical analyses were performed by SPSS (16) software. The Pearson correlation coefficient test was used to test the significant correlations for quantitative parameters. A value of P<0.05 was considered statistically significant. Results: Mean serum VEGF level in case and control groups was 153.8 ± 77.5 and 120.2± 45.4 pg/ml, respectively. Serum VEGF level was higher in beta thalassemia major (p= 0.037). Serum VEGF level was significantly higher in splenectomized patients (P=0.006). There was not any significant correlation between serum VEGF levels and Hemoglobin, WBC and platelet count and neither was with serum ferritin level (p>0.05). Conclusion: Serum VEGF level was higher in thalassemic patients. Splenectomized patients had higher serum VEGF levels than others.
References
1. 1. Galanello R, Origa R.Review: Beta-thalassemia. Orphanet J Rare Dis.2010;5(11):1-15.
2.Rezaee AR,Banoei MM,Khalili E,Houshmand M. Beta-thalassemia in iran: new insight into the role of genetic admixture and migration. The Scientific World Journal. 2012;2012 :1-7.
3.Fahmey SS,Naguib HF, Abdelshafy SS, Alashry RE. Vascular endothelial growth factor in children with thalassemia major. Mediterr J Hematol Infect Dis.2013; 5(1).
4.Kosaryan M,Vahidshahi K,Karami H,Alizadeh Forootan M,Ahangari M . Survival of thalassemic patients referred to the Boo Ali Sina Teaching Hospital, Sari, Iran. Hemoglobin.2007;31(4): 453-462.
5.Musallam KM, Taher AT, Rachmilewitz EA. β-thalassemia intermedia: a clinical perspective. Cold Spring Harb perspect Med. 2012; 2(7):1-15.
6.Ekatherina S, Trudel M, Felfly H,Lemsaddek W, Garcia D, CloutierG. Vascular Endothelial Dysfunction in b-Thalassemia Occurs Despite Increased eNOS Expression and Preserved Vascular Smooth Muscle Cell Reactivity to NO. PLoS ONE. 2012; 7(6): e38089.
7.Butthep P, Rummavas S, Wisedpanichkij R, Jindadamrongwech S, Fucharoen S, Bunyaratvej A. Increased circulating activated endothelial cells, vascular endothelial growth factor, and tumor necrosis factor in thalassemia. Am J Hematol. 2002; 70(2): 100-106.
8.Shitrit, D, Hannah T, Arielc K, Carinac L, Ariella Sulkes B Sh, et al. Correlation of vascular endothelial growth factor with the severity of thalassemia intermedia. Blood Coagul Fibrinolysis. 2008; 19(7): 611-614.
9.Kofler NM, Simons M. Angiogenesis versus arteriogenesis: neuropilin 1 modulation of VEGF signaling. F1000Prime Rep. 2015; 3(7): eCollection.
10.Dunst J, Becker A, Lautenschläger Ch,Markau S,Becker H, Fischer K ,et al., Anemia and elevated systemic levels of vascular endothelial growth factor (VEGF). Strahlenther Onkol. 2002;178(8): 436-441.
11.Olgar S,Kara A, Hicyilmaz H,Balta N,Canatan D. Evaluation of angiogenesis with vascular endothelial growth factor in patients with thalassemia major. Pediatr Int. 2010; 52(2): 247-251.
12.Dunst J, Pigorsch Sh, Hfinsgen H, Hintner I, Lautenschlfiger Ch,Becker A. Low hemoglobin is associated with increased serum levels of vascular endothelial growth factor (VEGF) in cancer patients. Strahlenther Onkol. 1999; 175(3): 93-96.
13.Van Royen N,Piek JJ, Schaper W,Bode Ch, Buschmann I. Arteriogenesis: mechanisms and modulation of collateral artery development. J Nucl Cardiol. 2001; 8(6) 687-693.
14. Rapisarda A, M.G., Role of the VEGF/VEGFR axis in cancer biology and therapy. Guidance Molecules in Cancer and Tumor Angiogenesis. 2012; 114: 237-255.
15.Risau W. Mechanisms of angiogenesis. Nature. 1997; 386(6626): 671-674.
16.Daniel B, Joel B, Leila M, Rabih CH. Current insights on the biology and clinical aspects of VEGF regulation. Vasc Endovascular surg. 2008; 42(6):517-30.
17.Stone J, Itin A,Alon T,Pe'Er J,Gnessin H,Chan-Ling T, et al. Development of retinal vasculature is mediated by hypoxia-induced vascular endothelial growth factor (VEGF) expression by neuroglia. J Neurosci.1995; 15(7): 4738-4747.
18.Park CC ,Bissell MJ,Barcellos-Hoff MH.The influence of the microenvironment on the malignant phenotype. Molecular medicine today. 2000; 6(8): 324-329.
19.Ramakrishnan S, Anand V, Roy S. Vascular Endothelial growth factor signaling in hypoxia and Inflammation. J Neuroimmune Pharmacology. 2014; 9(2): 142-160.
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |